 | The Evolving Lipids Landscape: Current and Emerging Nonstatins
Chair: Salim Virani, MD, FACC
The ever-expanding wide spectrum of treatment options for ASCVD has drastically changed the lipid-lowering landscape. Understanding the nuanced considerations for patient selection is now more important than ever. Come join the experts to hear the latest strategies on appropriately using new nonstatin agents in clinical practice. | |
| | | |
 | Tracking the CV Impact of SGLT2i's: Practice Essentials
Chair: Alison Bailey, MD, FACC
The rapid release of new trial results for sodium-glucose cotransporter 2 inhibitor (SGLT2i) and emerging indications demonstrate an exciting new treatment for patients at high cardiovascular risk. Join this expert-led session to gain insights on the latest science and practical applications you need to deliver cutting-edge therapy to your patients. | |
| | | |
 | What's New in HF Pharmacotherapies: The What, How, and Wow
Chair: Alanna Morris, MD, MSc, FACC
The treatment landscape for heart failure has evolved significantly, with exponential growth in clinical trials and therapeutic options. Join the experts as they help you navigate the new and complex management landscape, including understanding emerging therapies and their practical applications.
| |
| | | |
 | Anticoagulation Trivia from A to V: Management Strategies Across the Board
Chair: Geoff Barnes, MD, MSc, FACC
There are multiple challenges facing clinicians when selecting the best anticoagulation treatment strategy for their patients. Come test your knowledge and compete against your peers at this cross-cutting interactive session covering anticoagulation for AFib, PAD, VTE, and COVID.
| |
| | | |
 | Contemporary Approaches to Hypertrophic Cardiomyopathy: If You Can See It, You Can Treat It
Chair: Matthew W. Martinez, MD, FACC
This course, is chaired by Matthew W. Martinez, MD, FACC, will help you sharpen your diagnostic skills to recognize the characteristic signs and symptoms of hypertrophic cardiomyopathy. Our expert faculty will share the latest advancements in diagnosis and emerging therapies to provide timely treatment to patients with this underrecognized disease.
| |
| Contemporary Approaches to Cardiac Amyloidosis: If You Can See It, You Can Treat It
Chairs: Farooq Sheikh, MD, FACC and Frederick L. Ruberg, MD, FACC
This course, chaired by Farooq Sheikh, MD, FACC and Frederick L. Ruberg, MD, FACC, will help clinicians better recognize the signs and symptoms, interpret diagnostic findings, evaluate emerging treatment options, and establish referrals to accelerate treatment for patients with cardiac amyloidosis.
| |
The American College of Cardiology appreciates the educational grant support for the Clinical Spotlight Series:
Akcea Therapeutics, Inc., Alnylam Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC, Bristol-Myers Squibb and Pfizer Alliance, Cytokinetics, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp., MyoKardia, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
© 2021 American College of Cardiology Foundation. All rights reserved. |